Genetic Variants and Heart Disease Treatment
Author Information
Author(s): Tanner Rikki M., Lynch Amy I., Brophy Victoria H., Eckfeldt John H., Davis Barry R., Ford Charles E., Boerwinkle Eric, Arnett Donna K.
Primary Institution: University of Alabama at Birmingham
Hypothesis
Do MMP9 and MMP12 genetic variants affect cardiovascular disease outcomes in hypertensive patients treated with different antihypertensive drugs?
Conclusion
The study found interactions between antihypertensive drugs and MMP9 and MMP12 variants that may influence treatment decisions for cardiovascular disease.
Supporting Evidence
- Participants with the MMP9 R668Q AA genotype had a lower risk of combined CHD when treated with chlorthalidone.
- MMP9 R279Q GG genotype was associated with lower risk of combined CVD when treated with chlorthalidone.
- MMP12 N122S GG genotype showed increased rates of CHD when treated with lisinopril.
Takeaway
This study looked at how certain genes might change the way heart disease treatments work for people with high blood pressure.
Methodology
The study analyzed data from a randomized clinical trial involving hypertensive patients, assessing genetic variants and their interactions with antihypertensive treatments.
Potential Biases
Potential population substructure may affect the results, but randomization helps control for this.
Limitations
The study only examined four MMP polymorphisms and may not be generalizable to younger populations.
Participant Demographics
Participants were predominantly aged 55 or older, with 47% non-White and 46% female.
Statistical Information
P-Value
0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website